Enterprise Value
8.921M
Cash
9.684M
Avg Qtr Burn
-10.96M
Short % of Float
0.78%
Insider Ownership
2.02%
Institutional Own.
13.42%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ebopiprant (OBE022) Details Preterm labor | Phase 2b Update | |
YSELTY® (linzagolix) Details Benign tumor | Failed Discontinued | |
YSELTY® (linzagolix) Details Inflammatory disease, Endometriosis | Failed Discontinued |